Overview
- First book on the novel synthetic treatment of migraine
- Compares gepants with triptans or CGRP monoclonal antibodies
- Compares ditans with triptans
Part of the book series: Headache (HEAD)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (9 chapters)
-
Front Matter
Keywords
About this book
Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.
Editors and Affiliations
About the editors
Paolo Martelletti is Professor of Internal Medicine at the University 'La Sapienza' of Rome, and Director of the Regional Reference Headache Center at the Sant'Andrea University Hospital in Rome, Italy. He is now developing new research avenues for the study of factors for chronicity, comorbidities, and aspects of health economics in primary headaches; elaboration of rehabilitation protocols in patients with secondary headache as a consequence of medication overuse; study of innovative therapies for the acute treatment and prophylaxis of primary headaches. He is Editor of the Springer Headache book series and Editor-in-Chief of the Journal of Headache and Pain and Editor-in-Chief of Springer Nature Comprehensive Clinical Medicine.
​Lars Edvinsson is Professor of Internal Medicine at the Faculty of Medicine, Lund University Hospital, Sweden. He is a leading expert in the field of cerebral circulation and migraine and is world recognized for his work on vascular innervation and receptor regulation. His extensive research has been a major contributor to what is known about the roles of the cerebral vasculature in health and diseases such as stroke and primary headaches. Recently, his ground-breaking work on the sensory system has resulted in new medicine being introduced small molecular CGRP-blockers for acute attacks and antibodies towards CGRP or CGRP-receptors as prophylaxis chronic migraine.Bibliographic Information
Book Title: Novel Synthetic Drugs in Migraine
Editors: Paolo Martelletti, Lars Edvinsson
Series Title: Headache
DOI: https://doi.org/10.1007/978-3-030-95334-8
Publisher: Springer Cham
eBook Packages: Medicine, Medicine (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022
Hardcover ISBN: 978-3-030-95333-1Published: 28 April 2022
Softcover ISBN: 978-3-030-95336-2Published: 29 April 2023
eBook ISBN: 978-3-030-95334-8Published: 26 April 2022
Series ISSN: 2197-652X
Series E-ISSN: 2197-6538
Edition Number: 1
Number of Pages: IX, 109
Number of Illustrations: 5 b/w illustrations
Topics: Internal Medicine, Neurology, Emergency Medicine, Pain Medicine, Pharmacology/Toxicology